Hepatitis B
Conditions
Keywords
Long-term follow-up, Hepatitis B antibody persistence
Brief summary
The purpose of this study is to evaluate the persistence of anti-hepatitis B surface antigen (anti-HBs) antibodies 16, 17, 18, 19 and 20 years after administration of the first dose of the study vaccine. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Detailed description
The primary study was designed to evaluate the immunogenicity and protective efficacy of hepatitis B vaccine in newborns of HBeAg+ and HBsAg+ mothers in comparison with a historical control group. The present study is carried out to evaluate the anti-HBs persistence 16-20 years after the first vaccine dose and to further investigate the prevalence and incidence of other hepatitis B markers and the clinical significance of these at all time points from Year 16-20. No additional subjects will be recruited during this long-term follow-up study and no vaccine will be administered.
Interventions
BIOLOGICALEngerix™-B
In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 20 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who had received at least one dose of the study vaccine in the primary study (103860/064) * Written informed consent obtained from each subject before each blood sampling visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Years 17, 18, 19 and 20. | During this follow-up study, it was planned to collect data from Year 16 through to Year 20 after primary vaccination. By the time the study protocol was approved, it was too late to collect data on Year 16. Therefore, the table presents mean concentrations expressed in milli-international units/milliliter (mIU/mL) at years 17, 18, 19 and 20. |
| Prevalence of Serological Markers for Hepatitis B Infection | Years 17, 18, 19 and 20. | It was initially planned to collect data from Year 16 through to Year 20 after primary vaccination. By the time the study protocol was approved, it was too late to collect data on Year 16. Only the subjects positive for HBsAg or anti Hepatitis B core antigen (anti-HBc) were tested for HBeAg & anti-HBe |
| Clinical Review for Hepatitis B Infection Status | Over the entire 4 year follow up period (17 - 20 years) | Chronic hepatitis B (HB) carrier is defined as positive for anti-HBc AND HBsAg at two or more consecutive time points |
Countries
Thailand
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| HBV 5 Group neonates born to Hepatitis B surface antigen negative (HBsAg-) and Hepatitis B e antigen negative (HBeAg-) mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60) | 17 |
| HBV 2 Group neonates born to Hepatitis B surface antigen positive (HBsAg+) and Hepatitis B e antigen positive (HBeAg+) mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12) | 20 |
| HBV 1 Group neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60) | 17 |
| HBV 4 Group neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12) | 23 |
| HBV 3 Group neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60) | 29 |
| HBV 6 Group neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12) | 3 |
| Total | 109 |
Baseline characteristics
| Characteristic | HBV 5 Group | HBV 2 Group | HBV 1 Group | HBV 4 Group | HBV 3 Group | HBV 6 Group | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 16.5 years STANDARD_DEVIATION 0.51 | 16.6 years STANDARD_DEVIATION 0.5 | 16.5 years STANDARD_DEVIATION 0.51 | 16.4 years STANDARD_DEVIATION 0.51 | 16.8 years STANDARD_DEVIATION 0.44 | 16.7 years STANDARD_DEVIATION 0.58 | 16.6 years STANDARD_DEVIATION 0.5 |
| Gender Female | 7 Participants | 9 Participants | 11 Participants | 7 Participants | 18 Participants | 1 Participants | 53 Participants |
| Gender Male | 10 Participants | 11 Participants | 6 Participants | 16 Participants | 11 Participants | 2 Participants | 56 Participants |
Outcome results
Primary
Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations
During this follow-up study, it was planned to collect data from Year 16 through to Year 20 after primary vaccination. By the time the study protocol was approved, it was too late to collect data on Year 16. Therefore, the table presents mean concentrations expressed in milli-international units/milliliter (mIU/mL) at years 17, 18, 19 and 20.
Time frame: Years 17, 18, 19 and 20.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| HBV 5 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 17 | 87.6 mIU/mL |
| HBV 5 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 18 | 96.2 mIU/mL |
| HBV 5 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 19 | 37.4 mIU/mL |
| HBV 5 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 20 | 46.4 mIU/mL |
| HBV 2 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 19 | 34.5 mIU/mL |
| HBV 2 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 17 | 43.8 mIU/mL |
| HBV 2 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 18 | 63.9 mIU/mL |
| HBV 2 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 20 | 25.8 mIU/mL |
| HBV 1 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 18 | 121.6 mIU/mL |
| HBV 1 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 19 | 108.1 mIU/mL |
| HBV 1 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 17 | 143.4 mIU/mL |
| HBV 1 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 20 | 101.8 mIU/mL |
| HBV 4 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 17 | 34.4 mIU/mL |
| HBV 4 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 18 | 33.1 mIU/mL |
| HBV 4 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 19 | 22.5 mIU/mL |
| HBV 4 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 20 | 20.3 mIU/mL |
| HBV 3 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 17 | 90.9 mIU/mL |
| HBV 3 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 20 | 55.5 mIU/mL |
| HBV 3 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 19 | 62.1 mIU/mL |
| HBV 3 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 18 | 89.1 mIU/mL |
| HBV 6 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 17 | 10.6 mIU/mL |
| HBV 6 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 18 | 19.2 mIU/mL |
| HBV 6 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 20 | 12.8 mIU/mL |
| HBV 6 Group | Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations | Year 19 | 26.9 mIU/mL |
Primary
Clinical Review for Hepatitis B Infection Status
Chronic hepatitis B (HB) carrier is defined as positive for anti-HBc AND HBsAg at two or more consecutive time points
Time frame: Over the entire 4 year follow up period (17 - 20 years)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| HBV 5 Group | Clinical Review for Hepatitis B Infection Status | Chronic HB carriers among primary study responders | 0 participants |
| HBV 5 Group | Clinical Review for Hepatitis B Infection Status | Chronic HB carriers | 0 participants |
| HBV 2 Group | Clinical Review for Hepatitis B Infection Status | Chronic HB carriers among primary study responders | 0 participants |
| HBV 2 Group | Clinical Review for Hepatitis B Infection Status | Chronic HB carriers | 1 participants |
| HBV 1 Group | Clinical Review for Hepatitis B Infection Status | Chronic HB carriers | 1 participants |
| HBV 1 Group | Clinical Review for Hepatitis B Infection Status | Chronic HB carriers among primary study responders | 0 participants |
| HBV 4 Group | Clinical Review for Hepatitis B Infection Status | Chronic HB carriers among primary study responders | 0 participants |
| HBV 4 Group | Clinical Review for Hepatitis B Infection Status | Chronic HB carriers | 0 participants |
| HBV 3 Group | Clinical Review for Hepatitis B Infection Status | Chronic HB carriers | 0 participants |
| HBV 3 Group | Clinical Review for Hepatitis B Infection Status | Chronic HB carriers among primary study responders | 0 participants |
| HBV 6 Group | Clinical Review for Hepatitis B Infection Status | Chronic HB carriers among primary study responders | 0 participants |
| HBV 6 Group | Clinical Review for Hepatitis B Infection Status | Chronic HB carriers | 0 participants |
Primary
Prevalence of Serological Markers for Hepatitis B Infection
It was initially planned to collect data from Year 16 through to Year 20 after primary vaccination. By the time the study protocol was approved, it was too late to collect data on Year 16. Only the subjects positive for HBsAg or anti Hepatitis B core antigen (anti-HBc) were tested for HBeAg & anti-HBe
Time frame: Years 17, 18, 19 and 20.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBsAg Negative | 100 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBsAg Positive | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBeAg Negative | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBeAg Negative | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBsAg Negative | 100 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBsAg Positive | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBc Negative | 94.1 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBc Positive | 5.9 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBsAg Negative | 92.9 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBsAg Positive | 7.1 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBsAg Negative | 100 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBsAg Positive | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBc Negative | 93.7 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBc Positive | 6.3 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 5 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBsAg Positive | 5.9 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBsAg Negative | 94.1 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBc Positive | 25 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBsAg Positive | 6.3 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBsAg Negative | 93.7 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBeAg Positive | 20 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBc Negative | 76.5 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBsAg Positive | 23.5 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBsAg Negative | 76.5 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBc Positive | 31.3 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBsAg Negative | 100 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBc Positive | 23.5 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBsAg Positive | 0 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBeAg Negative | 80 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBc Positive | 23.5 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBc Negative | 75 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBc Negative | 68.7 Percentage of participants (%) |
| HBV 2 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBc Negative | 76.5 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBsAg Negative | 100 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBsAg Positive | 0 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBc Negative | 71.4 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBc Positive | 28.6 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBsAg Negative | 100 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBsAg Positive | 0 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBc Negative | 78.6 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBc Positive | 21.4 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBsAg Negative | 92.9 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBsAg Positive | 7.1 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBc Negative | 78.6 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBsAg Negative | 100 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBsAg Positive | 0 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBc Negative | 78.6 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBc Positive | 21.4 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBc Positive | 21.4 Percentage of participants (%) |
| HBV 1 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBsAg Negative | 85 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBsAg Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBsAg Positive | 15 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBsAg Negative | 100 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBeAg Negative | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBsAg Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBc Negative | 95 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBeAg Negative | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBsAg Negative | 100 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBsAg Negative | 78.9 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBsAg Positive | 21.1 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBeAg Negative | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBc Positive | 5 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBeAg Negative | 0 Percentage of participants (%) |
| HBV 4 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBsAg Negative | 96.3 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBsAg Positive | 3.6 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBeAg Negative | 80 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBsAg Positive | 3.7 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBsAg Positive | 17.9 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBeAg Positive | 20 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBsAg Negative | 96.4 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBsAg Negative | 82.1 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBsAg Negative | 84.6 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBsAg Positive | 15.4 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 3 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBsAg Negative | 75 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBsAg Positive | 25 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBsAg Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBeAg Negative | 100 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBsAg Negative | 100 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBeAg Negative | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBeAg Negative | 100 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 19, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBsAg Negative | 100 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBeAg Negative | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBsAg Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBeAg Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBsAg Negative | 100 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, Anti HBc Negative | 100 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, Anti HBeAg Negative | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBeAg Negative | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 20, HBeAg Negative | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBc Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, HBeAg Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 17, HBsAg Positive | 0 Percentage of participants (%) |
| HBV 6 Group | Prevalence of Serological Markers for Hepatitis B Infection | Year 18, Anti HBeAg Negative | 0 Percentage of participants (%) |